|
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure Clinical research trials and Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure. Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure clinical trial. Test subjects typically receive the most expert healthcare available for their Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure  Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
For Condition: Fulminant Hepatic Failure
Status: Recruiting
Sponsor(s): VitaGen ,
Synopsis: The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.
Details: Current treatment with modalities in Acute Liver Failure still carry unacceptable morbidity and mortality. It is hoped that by intervening with ELAD a patient will have an opportunity to be bridged to transplant or to avoid transplantation and to have their native liver recover.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Clinical diagnosis of Fulminant Hepatic Failure with encephalopathy, and coagulopathy. Exclusion Criteria: No evidence of chronic liver disease.
Total Enrollment: 18
Location and Contact Information:
Overall Study Official:
PatrickMaguire, Study Chair, VitaGen
University of Miami *Recruiting*
Miami, Florida, 33136
United States
Recruiting Guy Neff 305-355-5160
Massachusetts General Hospital *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting Winifred Williams 617-724-3833
University of Virginia *Recruiting*
Charlottesville, Virginia, 22908
United States
Recruiting Stephen Caldwell 434-924-2626
University of Chicago *Recruiting*
Chicago, Illinois, 60637
United States
Recruiting Michael Millis 773-702-6319
UCSD *Recruiting*
San Diego, California, 92103
United States
Recruiting Marquis Hart 619-543-5870
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Peter Linden 412-647-7899
Emory School of Medicine *Recruiting*
Atlanta, Georgia, 30322
United States
Recruiting Thomas Heffron 404-727-3599
Additional Information:
Study ID Numbers: CR-202;
Study Start Date: January 2002
Record last reviewed: January 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00030225
Other Fulminant Hepatic Failure Studies:
1. Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
Related Studies:
Other Fulminant Hepatic Failure Clinical Trials
Other Florida Clinical Trials
Other Miami Clinical Trials
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
|
|
|
|
|
|
|
|
